Annual Meeting On-Demand - Short Course #14 - Thyroid Molecular Cytopathology According to the 3rd Edition of The Bethesda System

The impact of molecular testing on thyroid cytology is well recognized. By probing genomic alterations, the major molecular test platforms have the potential to clarify the biologic nature of indeterminate thyroid nodules.

This session will illustrate the key concepts and use a practical case-based approach to address the following topics.

  • Molecular changes in thyroid neoplasia
  • Overview of molecular testing platforms in thyroid cancer
  • Benign Call Rate (BCR) and Molecular-Derived Risk of Malignancy (MDROM) and their application to thyroid cytopathology
  • Cancer prognostication using "Molecular Risk Groups" (MRGs)
  • Emerging role of molecular testing for Suspicious for Malignancy (Bethesda-V) cases and false negative molecular results
  • Interpretation of a "negative" molecular result and importance of surveillance even for MT-negative cases
  • Deviation from the usual genotype-phenotype expectation (e.g. RAS-like alterations and follicular-patterned neoplasms); usefulness of MT to refine surgical planning
  • Use of molecular testing results to refine a nodule's risk of adverse clinical outcomes and guide decisions regarding extent of surgery

Target Audience

This educational activity is designed for pathologists, cytopathologists, cytotechnologists, students and other members of the cytopathology community.

Learning Objectives

  • Provide updates on the characteristics and role of molecular testing within the framework of TBSRTC, 3rd edition.
  • Develop deeper insights into molecular testing results to improve the pre-surgical risk stratification of thyroid nodules.
  • Explain certain molecular profiles through case examples that have significance for diagnostic, prognostic, theranostic, and quality assurance purposes.
Course summary
Available credit: 
  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 California Credits
  • 1.50 CMLE
  • 1.50 Florida Credits
  • 1.50 Participant
Course opens: 
01/01/2026
Course expires: 
12/31/2028
Cost:
$125.00

Presenter(s):
N. Paul Ohori, MD
Michiya Nishino, MD, PhD 

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
The faculty, committee members, Executive Board and staff who are in position to control the content of this activity are required to disclose to the ASC and to learners any financial relationships that have occurred within the last 24 months with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The ASC has reviewed the disclosures and mitigated all relevant financial relationships.

The following individuals have reported financial relationships:
Israh Akhtar, MD, FIAC: Consultant - Astra Zeneca
Zaibo Li, MD, PhD: Consultant - PathAI, AlxMed; Board of Directors - Digital Pathology Association
Paul VanderLaan, MD, PhD: Consultant – Gala Therapeutics

The following individuals have reported no relevant financial relationships:
Kristen Atkins, MD, Catherine Bammert, PhD, CT, MB(ASCP), CT(IAC), Christine Booth, MD, Marilyn Bui, MD, PhD, Amy Clayton, MD, Jacqueline Cuda, BS, SCT(ASCP), Fang Fan, MD, PhD, Beverly Haigler-Daly, BS, CT(ASCP), Michael Henry, MD, Angelique Levi, MD, Xiaoying Liu, MD, Abberly Lott Limbach, MD, Maria Cecilia Lozano, MD, PhD, MIAC, Varsha Manucha, MD, Sean McNair, MPH, CT(ASCP), Sara Monaco, MD, Maheswari Mukherjee, PhD, MSc, BPT, SCT(ASCP)CM, Dianna Ng, MD, Michiya Nishino, MD, PhD, Christopher O'Conor, MD, PhD, Melissa Randolph, BS, SCT(ASCP), Michelle Reid, MD, MSc, Marilin Rosa, MD, Sinchita Roy-Chowdhuri, MD, PhD, Momin Siddiqui, MD, FIAC, Zoon Tariq, MD, Michael Thrall, MD, Gary Tse, MBBS, Christopher VandenBussche, MD, PhD, Philippe Vielh, MD, PhD, Joe Walker, Jr, MS, SCT(ASCP), Vivian Weiss, MD, PhD, Lisa Zhang, MD, David Kim, MD, Brie Kezlarian-Sach, MD, Hasan Bilal, MD, N. Paul Ohori, MD

The ASC staff associated with the development of content for this activity reported no relevant financial relationships.

ACCREDITATION AND DESIGNATION STATEMENTS

Continuing Medical Education (CME) Statement
The American Society of Cytopathology is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.  The American Society of Cytopathology designates this enduring educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

American Board of Pathology Maintenance of Certification (CC)
This product can help fulfill the CME requirements mandated by the American Board of Pathology Continuing Certification (CC) process.  Earn up to 1.5 Credit Hours.

Continuing Medical Laboratory Education (CMLE)
The ASC designates this activity for a maximum of 1.5 Continuing Medical Laboratory Education (CMLE) credit hours for non-physicians.  The CMLE credit hours meet the continuing education requirements for the ASCP Board of Registry Certification Maintenance Program. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Cytotechnologists with Licenses in Florida and California
This program is approved for 1.5 continuing education credits in the States of Florida and California.

Available Credit

  • 1.50 AMA PRA Category 1 Credit™
  • 1.50 California Credits
  • 1.50 CMLE
  • 1.50 Florida Credits
  • 1.50 Participant

Price

Cost:
$125.00
Please login or register to take this course.